Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Biotechnology
- Diagnostic
- Therapeutic
- Disease
- Diabetes Treatment
- Cellular
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 233478
License Grant
Licensor grants, to the extent not prohibited by the United States Government, an exclusive, worldwide, license in the License Field, under Licensors rights in Patent Rights to make, have made, use, sell, offer for sale and import Products; and, to the extent an exclusive license is not available toLicensee in a country, due to legal or regulatory action in such country, a non-exclusive license in such country in the License Field under Patent Rights to make, have made, use·, sell, offer for sale and import Products; and, a non-exclusive, worldwide fully paid-up license to use the Know-how in the License Field; and, the right to sub license Patent Right and Know-How licensed to Licensee.
License Property
Patents pertain to pancreatic stem cells for treatment of diabetes.
The term Product shall mean any article, device, composition, method or service the manufacture, use, or sale of which absent the licenses granted herein, would infringe a valid claim of any Patent Right, or, does not infringe a valid claim of any Patent Right licensed to Licensee, but the discovery, development, manufacture or use of which requires or materially employs non-public Know-how.
The patents are for Stem Cells of the Islets of Langerhans and Their Use in Treating Diabetes Mellitus, Stem Cells of the Islets of Langerhans and Their Use in Treating Diabetes, Stem Cells and Their use in Transplantation, and, Pancreatic Stem Cells and Their Use in Transplantation.
Field of Use
The term Licensed Field shall mean the diagnosis, treatment or prevention of human and animal diseases and conditions. The patents have specific Diabetes and Pancreatic application.
IPSCIO Record ID: 27800
License Grant
The Licensor, the Canadian University, sells and assigns to the Licensee all its right, title and interest in and to the Patent Rights.
License Property
Patent Rights means US provisional patent application no. 62/007,626 related to use of anti-aging glycopeptides to enhance beta cell health, survival and improve transplant outcomes, and all patents issuing from such application.
Field of Use
The Licensee's anti-aging glycopeptides, trademarked as AAGPsâ„¢, have been demonstrated to enhance the health and extend the life of biologically sensitive cells that have been subjected to acute stress conditions under laboratory protocols.
One area of use is to increase the number of stem cells available to convert into pancreatic islet cells, thereby increasing the number of islet cells that can be impl. Producing new islet cells has proven to be a difficult task. Differentiating pluripotent stem cells into islet cells has been accomplished in the laboratory and is still hoped to be the answer for treating or possibly curing type 1 diabetes.
This treatment for type 1 diabetes would be to transplant insulin-producing islet cells into the body. The Edmonton Protocol is a method of implanting pancreatic islets into the liver for the treatment of type 1 diabetes.
IPSCIO Record ID: 263
License Grant
The Hospital hereby grants the Licensee an exclusive, royalty-bearing license under its Patent Rights in the License Field and the License Territory.
License Property
Pathfinder Cells shall mean a mixed population of mammalian cells, with a mixed CD90 positive phenotype and CD34 negative phenotype, isolated using the methodology described in the patent WO/2006/120476, and which are capable of facilitating, or initiating the repair of mammalian tissue following, by way of example only, insult with an exogenous agent, or degenerative disease, or through the biological ageing processes.
Patent rights shall mean the U.S. Patent Application Number 11/438,790, filed on May 22, 2006 or the equivalent of such application as well as issued patent applications including U.S. Patent Application Number 11/410, 412, 10/984, 645, and 11/132, 687.
Field of Use
Pathfinder Cells are a newly identified mammalian cell type that have the ability to stimulate tissue regeneration in a number of different organs. PCs are not stem cells and are distinguishable from cell types being developed by other companies for use in regenerative medicine through cell surface and other markers.
IPSCIO Record ID: 522
License Grant
Licensor, a nonprofit medical research facility, hereby grants to Licensee an exclusive, worldwide license, including the right to sublicense, to make, use, sell, import, export or otherwise distribute Licensed Products; practice any method, process or procedure, and otherwise exploit the Scripps Patent Rights; and to have any of the foregoing performed on its behalf by a third party, in each case solely within the Field, subject to the terms of this Agreement.
License Property
Licensor is engaged in fundamental scientific biomedical and biochemical research, including research relating to pancreatic stem and progenitor cells.
Field of Use
Licensee is engaged in research and development of stem and progenitor cells for the diagnosis, treatment and prophylaxis of diseases and other conditions in humans and animals. A novel technology may facilitate the identification and isolation of pancreas stem and progenitor cells by using a mouse model that continuously regenerates the pancreas. We believe that stem cells produce the regeneration, in which case this animal model may be useful for identifying specific markers on the cell surface unique to the pancreas stem cells. We believe this may lead to the development of cell-based treatments for Type 1 diabetes and that portion of Type 2 diabetes characterized by defective secretion of insulin.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
